Portfolio company
Elephas Biosciences
United States · £31.6m raised
Raised
£31.6m
Latest stage
Series B
Rounds recorded
1
Backed by
5 investors
Sectors
About
This company develops a live tissue platform for predicting immunotherapy response to assist oncologists, researchers, and pharmaceutical developers in cancer treatment.
SourceFunding history · 1
Similar companies
Elephas
Elephas develops a live-tissue imaging platform to predict immunotherapy response for clinicians, researchers, and pharmaceutical companies by profiling live tumor biopsies ex vivo.
Prevision Medicine
This company develops a live-cell testing platform that provides personalised drug response reports to help oncologists select effective treatments for cancer patients.
Known Medicine
This company develops a platform using 3D cell culture and artificial intelligence to predict drug responses for oncologists and biopharmaceutical developers.
Kiyatec
This company develops 3D cell culture platforms to predict patient-specific responses to cancer therapies for oncologists and biopharmaceutical companies.
LiquidCell Dx
This company develops blood-based liquid biopsy tests for tumor microenvironment profiling to help pharmaceutical companies and clinical partners predict cancer therapy responses.
Pear Bio
The company develops a precision medicine platform using microfluidic chips and computer vision to predict cancer treatment efficacy for oncologists and pharmaceutical researchers.
PreComb
This company develops a precision oncology platform using patient-derived microtumour models and automated analysis to predict drug responses for biopharmaceutical firms and clinical institutions.
Orakl Oncology
This company develops a predictive platform using patient tumor avatars and data to help pharmaceutical firms accelerate and de-risk cancer drug development.
